HopeStage
Back to all studies
CompletedNCT02168127

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

About this titleRead the official source — NCT02168127

This study evaluated the safety and effectiveness of PRC-063 for people with ADHD.

Medication studyAges 12+United States + Canada
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of PRC-063 for people with ADHD.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 12 years. Other eligibility criteria applied.

Listed locations
Los Angeles and 34 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2014
Recruitment status
Completed
Enrollment listed in the registry
360
Sponsor
Rhodes Pharmaceuticals, L.P.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
Over 12 Years
Official registry ID
NCT02168127
Official title
Show the full official title

A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles, United States · National City, United States · Newport Beach, United States

30 more locations
  • Orange, United States
  • Bradenton, United States
  • Gainesville, United States
  • Jacksonville, United States
  • Maitlin, United States
  • Orlando, United States
  • Boise, United States
  • Las Vegas, United States
  • New York, United States
  • Raleigh, United States
  • Cincinnati, United States
  • Oklahoma City, United States
  • Portland, United States
  • Salem, United States
  • Memphis, United States
  • Austin, United States
  • Dallas, United States
  • Houston, United States
  • Lubbock, United States
  • Clinton, United States
  • Salt Lake City, United States
  • Woodstock, United States
  • Herndon, United States
  • Friday Harbor, United States
  • Kirkland, United States
  • Vancouver, Canada
  • Niagara Falls, Canada
  • Ottawa, Canada
  • Whitby, Canada
  • Sherbrooke, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of PRC-063 for people with ADHD.

Who is behind this study?

The study sponsor is Rhodes Pharmaceuticals, L.P.

Did this study involve medication?

Yes. The study involved medication, including Drug: PRC-063 and PRC-063.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 12 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies